TriangleELI-002 7P (NCT07671339)
ELI-002 7P trial for KRAS-Mutant Pancreatic Cancer (NCT07671339). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with pancreatic cancer that carries a KRAS mutation.
The idea: ELI-002 7P is a vaccine given as a shot under the skin, aimed at mutated KRAS. It is combined with mFOLFIRINOX chemotherapy given before surgery. Some patients also get tislelizumab, an immunotherapy antibody given by vein.
The study looks at safety, and whether the treatment works against the cancer.
This phase 1 study plans 20 patients. At Memorial Sloan Kettering Cancer Center in New York, Kevin Soares leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.